Clinical Trials Logo

Lysosomal Storage Diseases clinical trials

View clinical trials related to Lysosomal Storage Diseases.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04283227 Active, not recruiting - Clinical trials for Metachromatic Leukodystrophy

OTL-200 in Patients With Late Juvenile Metachromatic Leukodystrophy (MLD)

Start date: January 17, 2022
Phase: Phase 3
Study type: Interventional

OTL-200 is a cryopreserved dispersion for infusion containing autologous CD34+ cell enriched population that contains haematopoietic stem and progenitor cells (HSPC) transduced ex vivo using a lentiviral vector encoding the human arylsulfatase A (ARSA) gene. MLD is an autosomal recessive lysosomal storage disorder (LSD) characterized by severe and progressive demyelination affecting the central and peripheral nervous system. The aim of this clinical study is to assess the pharmacodynamic effect and long-term clinical efficacy and safety of OTL-200 in Late Juvenile MLD patients.

NCT ID: NCT04093349 Active, not recruiting - Pompe Disease Clinical Trials

A Gene Transfer Study for Late-Onset Pompe Disease (RESOLUTE)

Start date: October 1, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, and efficacy of a single intravenous infusion of SPK-3006 in adults with clinically moderate, late-onset Pompe disease receiving enzyme replacement therapy (ERT). Participants will be treated in sequential, dose-level cohorts.

NCT ID: NCT03897361 Active, not recruiting - Cystinosis Clinical Trials

Stem Cell Gene Therapy for Cystinosis

Start date: July 8, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This study is a Phase 1/2 clinical trial that will assess the safety and efficacy of enriched gene-corrected hematopoietic stem cells isolated from patients affected with cystinosis. (Investigational Product: CTNS-RD-04 or CTNS-RD-04-LB, where the suffix "-LB" stands for LentiBOOST)

NCT ID: NCT03812042 Active, not recruiting - Clinical trials for Lysosomal Storage Diseases

Screening of Lysosomal Storage Disorders Diseases in Minority Groups

Start date: March 17, 2016
Phase:
Study type: Observational

Aim is to undertake a screening study that identifies undiagnosed patients with LSDs and determine the prevalence of these diseases with special focus on underrepresented minority groups.

NCT ID: NCT03392987 Active, not recruiting - Clinical trials for Metachromatic Leukodystrophy

A Safety and Efficacy Study of Cryopreserved OTL-200 for Treatment of Metachromatic Leukodystrophy (MLD)

Start date: January 25, 2018
Phase: Phase 2
Study type: Interventional

OTL-200 is autologous CD34+ cells transduced with lentiviral vector containing human arylsulfatase A (ARSA) complementary deoxyribonucleic acid (cDNA) used for the treatment of MLD. MLD is an autosomal recessive lysosomal storage disorder (LSD) characterized by severe and progressive demyelination affecting the central and peripheral nervous system. This study will assess safety and efficacy of treatment using cryopreserved formulation of OTL-200 in pediatric subjects with pre-symptomatic Early Onset MLD (Late Infantile (LI) to Early Juvenile (EJ) MLD) and early symptomatic EJ MLD.

NCT ID: NCT01560182 Active, not recruiting - Clinical trials for Metachromatic Leukodystrophy

Gene Therapy for Metachromatic Leukodystrophy (MLD)

Start date: April 9, 2010
Phase: Phase 1/Phase 2
Study type: Interventional

This Phase I/II clinical trial consists of the application of lentiviral vector-based gene therapy to patients affected by Metachromatic Leukodystrophy (MLD), a rare inherited Lysosomal Storage Disorder (LSD) resulting from mutations in the gene encoding the Arylsulfatase A (ARSA) enzyme. The medicinal product consists of autologous CD34+ hematopoietic stem/progenitor cells in which a functional ARSA cDNA is introduced by means of 3rd generation VSV-G pseudotyped lentiviral vectors.